drugset / Trial / NCT00305019
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clevudine | Small molecule | 30 mg | — |
| Subject | Clevudine | Small molecule | 50 mg | — |